In a striking courtroom drama unfolding in New Jersey federal court, Sandoz Inc. has accused biopharmaceutical giant United Therapeutics Corp. of adding “poison” to the market, effectively thwarting the sales of Sandoz’s generic hypertension drug. The two companies are entrenched in a legal battle, with more than $160 million in damages at stake, according to statements made during the opening of a bench trial on Monday.
Sandoz Says Biopharma Biz Added ‘Poison’ To Market: The Core of the Conflict
The trial, overseen by U.S. District Judge Brian R. Martinotti, aims to ascertain the financial damages incurred by Sandoz after United Therapeutics was found to have violated several laws, including the Sherman Antitrust Act. The conflict centers around the generic drug treprostinil, used to treat pulmonary arterial hypertension, which Sandoz introduced to the market. However, United Therapeutics, the manufacturer of the branded counterpart Remodulin, has been accused of blocking access to necessary delivery devices, compelling patients to rely on a less effective intravenous method.
We are The People's Media. USA Herald covers everything from breaking news to investigative journalism. We also report on politics on the State and National levels.
